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DLL4-mediated NOTCH1 signaling represents an essential pathway for vascular development and has emerged as
an attractive target for angiogenesis-based cancer therapies. However, newly reported toxicity findings raise safety
concerns of chronic pathway blockade. Lessons learned from the development of g-secretase inhibitors (GSIs)
might offer insights into how to safely harness this important signaling pathway.
DLL4/NOTCH1 signaling pathway in angiogenesis
In metazoans, the evolutionarily conserved NOTCH
pathway functions as an essential mechanism to regulate
numerous cell fate/lineage decisions during embryogen-
esis, postnatal development, and in the maintenance of
adult tissue homeostasis. NOTCH receptors are normally
constrained in a dormant state. Ligand binding exposes
the ADAM protease cleavage site that is normally buried
within the negative regulatory region (NRR)[1]. Subse-
quent intramembrane cleavage catalyzed by g-secretase, a
multisubunit protein complex, permits the release of the
intracellular portion (NICD) from the cell membrane and
its entry into the nucleus where it forms a transcriptional
activation complex. In mammals, the NOTCH signaling
apparatus consists of four single-pass transmembrane
receptors (NOTCH1-4) and at least five membrane-
anchored ligands (Jagged1, 2 and Delta-like or DLL1, 3
and 4). Despite the apparent redundancy of multiple
NOTCH ligands and receptors expressed in the vascular
system, recent studies have revealed that the DLL4-
NOTCH 1 interaction appears to be the dominant func-
tioning component in the vascular system. DLL4 was
initially identified as an endothelium-specific NOTCH
ligand [2-5]. Haploinsufficiency of Dll4 in mice results in
early embryonic lethality due to severe vascular defects
including impaired arteriogenesis, disrupted vascular
hierarchy, and enhanced vascular density with reduced
vessel caliber [2,6,7]. This uniquely non-redundant role
of DLL4 goes beyond early embryonic development. Stu-
dies utilizing a DLL4-selective antagonistic antibody
demonstrate that DLL4 is also essential for early postna-
tal vascular development, angiogenesis during pathologi-
cal wound healing (unpublished observations) and tumor
angiogenesis [8]. Compared to DLL4, NOTCH1 is more
broadly expressed and targeted disruption of Notch1
results in vascular defects similar to what has been
observed with Dll4 deficiency [9,10]. Moreover, results
from recent work using paralogue-specific antibodies
indicate that NOTCH1 inhibition alone is sufficient to
disrupt angiogenesis [11].
Studies in multiple model systems have revealed
important insights into the function of Dll4/NOTCH1
signaling in angiogenesis and the underlying mechanism
of vascular defects resulting from attenuated DLL4/
NOTCH1 activity [11,12]. Excessive angiogenic sprout-
ing, branching and increased endothelial cell proliferation
are commonly associated with blockade of DLL4/
NOTCH 1 signaling. Signaling induced by DLL4 through
NOTCH1 causes downregulation of VEGFR2, whereas
blocking DLL4 signaling leads to increased expression of
VEGFR2 and VEGFR3 [13]. Therefore, DLL4/NOTCH1
signaling is apparently required to restrain the magnitude
of response of endothelial cells to angiogenic stimuli. The
chaotic angiogenesis resulting from DLL4/NOTCH1
blockade may reflect unrestricted VEGF signaling and
disruption of a dynamic balance between tip cells and
stalk cells during angiogenic sprouting [14].
Therapeutic promise
The initial speculation of DLL4 signaling involvement in
tumor angiogenesis came from expression analyses of
DLL4 [12]. Results from a flurry of recent studies con-
firmed that targeting DLL4/NOTCH1 signaling has a
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profound impact on tumor angiogenesis and growth.
Pathway blockade was achieved using either a DLL4-
selective neutralizing antibody [8,15,16], a NOTCH1-
selective antagonistic antibody[11], a soluble DLL4
fusion protein[17,18], or a soluble NOTCH fusion pro-
tein[19]. These reagents demonstrated broad and robust
anti-tumor activity in a wide variety of tumor models.
While most of the current anti-angiogensis approaches
act through a reduction or elimination of tumor blood
vessels, DLL4 blockade results in the formation of a non-
functional vasculature incapable of supporting tumor
growth (Figure 1). Histological analysis of tumors treated
with DLL4/NOTCH1 inhibitors has revealed that the
reduced tumor growth is associated with an apparent
increase in tumor vascular density. However, labeling
with an intravascular tracer has demonstrated these vas-
cular structures to be poorly perfused [8,11,17,18]. Inade-
quate vascular function was also reflected by the
increased hypoxia observed in tumors treated with solu-
ble DLL4 [17]. Two major changes following DLL4/
NOTCH1 blockade might contribute to the defective
function of the tumor vasculature: impairment of lumen
formation and promotion of a chaotic vascular network.
Impaired lumen formation was described in the aortas of
Dll4+/- embryos [2]. Antagonizing DLL4/NOTCH1 also
caused a morphological change of endothelial sprouts
formed in an in vitro 3D culture system, with the luminal
space being absent or greatly reduced [8]. Conceivably, a
similar change in tumor vessels may lead to a reduction
in vessel lumen size that is incompatible with the passage
of red blood cells. Indeed, tumor vascular histology and
imaging studies have revealed a shift to smaller vessel
calibers and inefficient blood flow in anti-DLL4 treated
tumors [20] (unpublished observations). Since inhibition
of DLL4 leads to excessive branching of tumor vessels,
the other plausible cause of inefficient blood flow could
be the manifestation of a chaotic vascular network lack-
ing a functional hierarchy. DLL4 blockade could worsen
the already impaired vascular communication in the
tumor microvascular network and lead to exacerbated
functional shunting, a suspected primary cause of dys-
functional microcirculation and local hypoxia in cancer
[21].
In addition to tumor studies using anti-DLL4 as a sin-
gle agent, additive anti-tumor activity was observed in
combination with anti-VEGF therapy in a majority of
tested tumor models. Since angiogenic sprouting after
DLL4 blockade remains a VEGF-dependent process [8],
DLL4 inhibition may increase the dependency of the
tumor microvasculature on a VEGF-mediated survival
signal. In anti-Dll4 treated neonatal mouse retinas, there
was a defect in arteriogenesis with a complete absence of
pericyte coverage of the retinal vessels [8]. Soluble DLL4
was also able to reduce the recruitment of pericytes in a
murine xenograft tumor model [18]. Therefore, DLL4
blockade may impair the remodeling of the tumor vascu-
lature to become more mature and stable, resulting in
increased vulnerability of tumor vessels to VEGF block-
ade. In tumors targeted by DLL4/NOTCH1 inhibition,
the hyperproliferative state of endothelial cells, together
with the reduced protection of the tumor endothelium by
supporting cells, may render the tumor vasculature more
susceptible to agents that selectively target proliferating
cells. Indeed, anti-DLL4 in combination with chemother-
apy shows enhanced anti-tumor activity in preclinical
tumor models despite the concern that reduced perfusion
of tumor vessels might interfere with the delivery of ther-
apeutic agents [15,16].
Existing data support the endothelial cell-autonomous
role for DLL4/NOTCH1 signaling in restricting the
angiogenic response [22]. The NOTCH pathway has
been implicated in a variety of human cancers in con-
nection with the genetic alterations and epigenetic
events that lead to either constitutive NOTCH activa-
tion or sensitized response to ligand-induced activation
[12]. Interestingly, a recent study has suggested that
DLL4 blockade may reduce tumor-initiating cell fre-
quency in certain xenograft models [15,16]. At present,
however, the mechanism underlying DLL4-mediated
tumor initiation and/or progression remains unclear.
Safety challenges
Targeting a key step in the generation of amyloidogenic
peptides and the proteolytic activation of NOTCH signal-
ing, a number of GSIs are currently in preclinical and clin-
ical development for indications ranging from Alzheimer
disease to T-cell acute lymphoblastic leukemia (T-ALL)
[23]. A major hurdle to the therapeutic development of
GSIs has been the on-target toxicity in the gastrointestinal
Figure 1 Potential effects of DLL4/NOTCH1blockade on tumor
vasculature.
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tract. Inhibition of NOTCH signaling results in goblet cell
metaplasia due to the skewed differentiation of epithelial
cells in the intestinal crypts away from an enterocyte fate
and towards that of a secretory goblet cell [24]. Develop-
ment of goblet cell metaplasia requires simultaneous dis-
ruption of both Notch1 and Notch2 [25]. Because GSIs
indiscriminately block all NOTCH receptors, targeted
inhibition of individual receptors might help to alleviate
the observed gut toxicity. Using paralogue-specific anti-
NOTCH antibodies, Wu et al recently showed that selec-
tive NOTCH1 inhibition resulted in only mild goblet cell
metaplasia, representing an important progress in over-
coming the toxicity associated with pan-Notch inhibitors
[11]. Recently, Radtke’s group identified DLL1 and DLL4
as the key physiological ligands that mediate NOTCH sig-
naling in the mouse intestinal epithelium [26]. Intestine-
specific inactivation of either Dll4 or Jag1 had no obvious
phenotype, while loss of Dll1 resulted in a moderate
increase in goblet cell numbers. Dll1-Dll4 double knock-
out mice developed intestinal abnormalities to a degree
similar to Notch1-Notch2 compound mutant mice [26].
These findings are consistent with earlier work showing
that neutralizing anti-DLL4 antibodies had no discernable
impact on goblet cell differentiation and/or the prolifera-
tion of crypt progenitor cells [8].
While selective inhibition of DLL4 apparently avoids the
gut toxicity that plagued the therapeutic application of
GSIs, other safety concerns have been raised [27]. Admin-
istration of a DLL4-specific neutralizing antibody caused a
rapid and significant change in mouse liver gene expres-
sion, including the upregulation of endothelium- specific
genes as well as genes implicated in proliferation and cell
cycle regulation. More importantly, mice, rats and cyno-
molgus monkeys exposed to anti-DLL4 antibody devel-
oped histopathological changes in the liver, including
profound sinusoidal dilation and centrilobular hepatocyte
atrophy [27]. These changes are believed to be a class
effect of inhibiting DLL4 signaling through NOTCH1,
since similar changes were also observed when DLL4/
NOTCH1 signaling was inhibited by agents targeting
NOTCH1 or g-secretase. Along with the histological find-
ings, hepatic clinical pathology changes were observed in
treated animals. These findings suggest that DLL4 signal-
ing is essential for maintaining the structural and func-
tional integrity of the liver sinusoidal endothelium as well
as hepatocyte homeostasis. Since it has been documented
that some chemotherapy agents could cause liver sinusoi-
dal dilation or other types of liver damage [28], extra pre-
caution should be taken when combination therapy is
administered.
Besides the liver clinical- and histopathology changes
observed upon exposure to anti-DLL4 antibody, other
concerning safety signals were seen following prolonged
treatment. Most strikingly, skin lesions with features of
vascular neoplasms were observed in male rats. In addi-
tion, rare tumors with similar features were identified in
heart and lung [27]. Among the species tested, which
included mice, rats and monkeys, the proliferative vascu-
lar lesions were reported only in rats after 8 weeks of
continuous anti-DLL4 exposure. However, the potential
consequences of longer drug exposure in other species
remain uncertain. In clinical trials, patients treated with
semagacestat (LY450139), a g-secretase inhibitor, had an
increased risk of skin cancer [29]. A recent study employ-
ing an elegant genetic model showed that loss of Notch1
caused widespread vascular tumors, particularly in the
liver, further underscoring the potential safety concerns
associated with continuous blockade of NOTCH1 signal-
ing [30].
Accumulating evidence suggests that DLL4-mediated
NOTCH signaling is not restricted to the vascular com-
partment. Recent genetic studies have identified DLL4
expressed by thymic epithelial cells as the essential and
nonredundant NOTCH1 ligand responsible for intrathy-
mic T cell development [31,32]. Consistent with DLL4
genetic inactivation, anti-DLL4 treatment resulted in a
complete blockade of T cell development coupled with
ectopic appearance of immature B cells in the thymus
(unpublished observations). In addition, DLL4 together
with DLL1 regulate NOTCH signaling in the intestinal
crypt [26]. The recognition of a broader role for DLL4-
mediated NOTCH signaling raises the concern that on-
target toxicity of DLL4 inhibition could extend beyond the
endothelium.
While preclinical models have revealed the potential
toxicities associated with DLL4/NOTCH1 blockade, safety
findings in humans have just begun to emerge from recent
clinical trials. DLL4 targeting antibodies, OMP-21M18
and REGN421, have entered clinical development in
recent years. In a Phase I study of OMP-21M18, 28% of
patients experienced grade III asymptomatic hypertension,
a condition that has not been described in preclinical stu-
dies [33]. Since hypertension is a known dose-limiting side
effect of anti-VEGF therapy [34,35], patients receiving
combination therapy of anti-DLL4 and anti-VEGF should
be carefully monitored.
Potential path forward for targeting DLL4/
NOTCH1
Preclinical studies have suggested that DLL4/NOTCH1
blockade could augment the efficacy of anti-VEGF in
“sensitive” tumors. DLL4/NOTCH1 blockade may also
have the potential to enhance the effects of chemother-
apy or other targeted therapies in tumors that are either
intrinsically less dependent on VEGF or have progressed
due to a shift to dependency on other angiogenic path-
ways. While significant safety concerns have been raised
in recent preclinical studies, the full therapeutic potential
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of targeting DLL4/NOTCH1 should be further explored
given its remarkable impact on the tumor vasculature
and tumor growth in preclinical models. Lessons learned
from the preclinical and clinical development of GSIs
may offer some clues for a potential path forward. Since
it is generally believed that the outcome of Notch signal-
ing is dependent on context and the degree of activation,
it is possible that partial pathway inhibition might ame-
liorate the toxicities associated with stringent and contin-
uous pathway blockade while maintaining efficacy.
Indeed, Cullion et al were able to show that a GSI dosing
schedule with drug holidays largely avoided the gut toxi-
city while maintaining significant efficacy in mouse
T-ALL models [36,37]. It will be interesting and exciting
to determine if strategies based on the same principle
could expand the therapeutic window of selective target-
ing of DLL4/NOTCH1. The other remarkable observa-
tion from Ferrando’s group was that dexamethasone
protected mice against GSI-induced gut toxicity by shift-
ing differentiation away from goblet cell development
[38]. Since the effects of DLL4/NOTCH1 blockade might
be partly attributed to enhanced VEGF signaling, anti-
VEGF may have the potential to protect against anti-
DLL4 mediated toxicity. Interestingly, it has been
reported that bevacizumab protects against injury in
patients treated with oxaliplatin-based chemotherapy,
which is known to cause liver sinusoidal dilation [39].
Finally, it is important to point out that, given the potent
effect of DLL4/NOTCH1 blockade and its potential
safety implications, future development of anti-DLL4/
NOTCH1 therapeutics will require careful monitoring of
patient safety until the relevance and/or translatability of
observed preclinical toxicity concerns are better under-
stood in the clinical setting.
Acknowledgements
The author would like to thank Weilan Ye, Jessica Couch and Kevin Leong
for valuable suggestions and critical reading of the manuscript.
Competing interests
The author declares that they have no competing interests.
Received: 15 April 2011 Accepted: 8 August 2011
Published: 8 August 2011
References
1. Gordon WR, Vardar-Ulu D, Histen G, Sanchez-Irizarry C, Aster JC,
Blacklow SC: Structural basis for autoinhibition of Notch. Nat Struct Mol
Biol 2007, 14:295-300.
2. Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM,
Murphy AJ, Adams NC, Lin HC, Holash J, Thurston G, Yancopoulos GD:
Haploinsufficiency of delta-like 4 ligand results in embryonic lethality
due to major defects in arterial and vascular development. Proc Natl
Acad Sci USA 2004, 101:15949-15954.
3. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D: Delta4,
an endothelial specific notch ligand expressed at sites of physiological
and tumor angiogenesis. Differentiation 2001, 69:135-144.
4. Rao PK, Dorsch M, Chickering T, Zheng G, Jiang C, Goodearl A, Kadesch T,
McCarthy S: Isolation and characterization of the notch ligand delta4. Exp
Cell Res 2000, 260:379-386.
5. Shutter JR, Scully S, Fan W, Richards WG, Kitajewski J, Deblandre GA,
Kintner CR, Stark KL: Dll4, a novel Notch ligand expressed in arterial
endothelium. Genes Dev 2000, 14:1313-1318.
6. Duarte A, Hirashima M, Benedito R, Trindade A, Diniz P, Bekman E, Costa L,
Henrique D, Rossant J: Dosage-sensitive requirement for mouse Dll4 in
artery development. Genes Dev 2004, 18:2474-2478.
7. Krebs LT, Shutter JR, Tanigaki K, Honjo T, Stark KL, Gridley T:
Haploinsufficient lethality and formation of arteriovenous malformations
in Notch pathway mutants. Genes Dev 2004, 18:2469-2473.
8. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J,
Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JAS, de
Sauvage F, Plowman G, Yan M: Inhibition of Dll4 signalling inhibits
tumour growth by deregulating angiogenesis. Nature 2006,
444:1083-1087.
9. Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, Sundberg JP,
Gallahan D, Closson V, Kitajewski J, Callahan R, Smith GH, Stark KL, Gridley T:
Notch signaling is essential for vascular morphogenesis in mice. Genes
Dev 2000, 14:1343-1352.
10. Limbourg FP, Takeshita K, Radtke F, Bronson RT, Chin MT, Liao JK: Essential
role of endothelial Notch1 in angiogenesis. Circulation 2005,
111:1826-1832.
11. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, Finkle D,
Venook R, Wu X, Ridgway J, Schahin-Reed D, Dow GJ, Shelton A, Stawicki S,
Watts RJ, Zhang J, Choy R, Howard P, Kadyk L, Yan M, Zha J, Callanhan CA,
Hymowitz SG, Siebel CW: Therapeutic antibody targeting of individual
Notch receptors. Nature 2010, 464:1052-1057.
12. Yan M, Plowman GD: Delta-like 4/Notch signaling and its therapeutic
implications. Clin Cancer Res 2007, 13:7243-7246.
13. Jakobsson L, Bentley K, Gerhardt H: VEGFRs and Notch: a dynamic
collaboration in vascular patterning. Biochem Soc Trans 2009,
37:1233-1236.
14. Jakobsson L, Franco CA, Bentley K, Collins RT, Ponsioen B, Aspalter IM,
Rosewell I, Busse M, Thurston G, Medvinsky A, Schulte-Merker S, Gerhardt H:
Endothelial cells dynamically compete for the tip cell position during
angiogenic sprouting. Nat Cell Biol 2010, 12:943-953.
15. Fischer M, Yen WC, Kapoun AM, Wang M, O’Young G, Lewicki J, Gurney A,
Hoey T: Anti-DLL4 Inhibits Growth and Reduces Tumor-Initiating Cell
Frequency in Colorectal Tumors with Oncogenic KRAS Mutations. Cancer
Res 2011, 71:1520-1525.
16. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M,
Lazetic S, Park IK, Sato A, Wang X, Clarke MF, Lewicki J, Gurney A: DLL4
blockade inhibits tumor growth and reduces tumor-initiating cell
frequency. Cell Stem Cell 2009, 5:168-177.
17. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW,
Lin HC, Yancopoulos GD, Thurston G: Blockade of Dll4 inhibits tumour
growth by promoting non-productive angiogenesis. Nature 2006,
444:1032-1037.
18. Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R,
Djokovic D, Borges C, Ley EJ, Duarte A, Gill PS: Inhibition of Dll4 mediated
signaling induces proliferation of immature vessels and results in poor
tissue perfusion. Blood 2007.
19. Funahashi Y, Hernandez SL, Das I, Ahn A, Huang J, Vorontchikhina M,
Sharma A, Kanamaru E, Borisenko V, Desilva DM, Suzuki A, Wang X,
Shawber CJ, Kandel JJ, Yamashiro DJ, Kitajewski J: A notch1 ectodomain
construct inhibits endothelial notch signaling, tumor growth, and
angiogenesis. Cancer Res 2008, 68:4727-4735.
20. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S,
Turley H, Heikamp E, Hainfellner JA, Harris AL: Delta-like 4 Notch ligand
regulates tumor angiogenesis, improves tumor vascular function, and
promotes tumor growth in vivo. Cancer Res 2007, 67:11244-11253.
21. Pries AR, Hopfner M, le Noble F, Dewhirst MW, Secomb TW: The shunt
problem: control of functional shunting in normal and tumour
vasculature. Nat Rev Cancer 2010, 10:587-593.
22. Siekmann AF, Lawson ND: Notch signalling limits angiogenic cell
behaviour in developing zebrafish arteries. Nature 2007, 445:781-784.
23. Shih Ie M, Wang TL: Notch signaling, gamma-secretase inhibitors, and
cancer therapy. Cancer Res 2007, 67:1879-1882.
Yan Vascular Cell 2011, 3:17
http://www.vascularcell.com/content/3/1/17
Page 4 of 5
24. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H,
Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H: Notch/gamma-
secretase inhibition turns proliferative cells in intestinal crypts and
adenomas into goblet cells. Nature 2005, 435:959-963.
25. Riccio O, van Gijn ME, Bezdek AC, Pellegrinet L, van Es JH, Zimber-Strobl U,
Strobl LJ, Honjo T, Clevers H, Radtke F: Loss of intestinal crypt progenitor
cells owing to inactivation of both Notch1 and Notch2 is accompanied
by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep 2008,
9:377-383.
26. Pellegrinet L, Rodilla V, Liu Z, Chen S, Koch U, Espinosa L, Kaestner KH,
Kopan R, Lewis J, Radtke F: Dll1- and dll4-mediated notch signaling are
required for homeostasis of intestinal stem cells. Gastroenterology 2011,
140:1230-1240 e1237.
27. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB,
Niessen K, Plowman GD: Chronic DLL4 blockade induces vascular
neoplasms. Nature 2010, 463:E6-7.
28. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C,
Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L,
Curley SA, Abdalla EK: Chemotherapy regimen predicts steatohepatitis
and an increase in 90-day mortality after surgery for hepatic colorectal
metastases. J Clin Oncol 2006, 24:2065-2072.
29. Osherovich L: Notch nicked again. SciBx 2011, 4:1-2.
30. Liu Z, Turkoz A, Jackson EN, Corbo JC, Engelbach JA, Garbow JR, Piwnica-
Worms DR, Kopan R: Notch1 loss of heterozygosity causes vascular
tumors and lethal hemorrhage in mice. J Clin Invest 2011, 121:800-808.
31. Hozumi K, Mailhos C, Negishi N, Hirano K, Yahata T, Ando K, Zuklys S,
Hollander GA, Shima DT, Habu S: Delta-like 4 is indispensable in thymic
environment specific for T cell development. J Exp Med 2008,
205:2507-2513.
32. Koch U, Fiorini E, Benedito R, Besseyrias V, Schuster-Gossler K, Pierres M,
Manley NR, Duarte A, Macdonald HR, Radtke F: Delta-like 4 is the essential,
nonredundant ligand for Notch1 during thymic T cell lineage
commitment. J Exp Med 2008, 205:2515-2523.
33. Smith D, Eisenberg P, Stagg R, Manikhas G, Pavlovskiy A, Sikic B, Kapoun A,
Benner S: A First-In-human, phase I trial of the anti-DLL4 antibody (OMP-
21M18) targeting cancer stem cells in patients with advanced solid
tumors. 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer
Therapeutics, Nov 16-19, 2010 Berlin, Germany 2010.
34. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S: Increased risk of high-grade
hypertension with bevacizumab in cancer patients: a meta-analysis. Am
J Hypertens 2010, 23:460-468.
35. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath E,
Quinn DI, Gandara DR: Phase II study of Aflibercept (VEGF-Trap) in
patients with recurrent or metastatic urothelial cancer, a California
Cancer Consortium Trial. Urology 2010, 76:923-926.
36. Aster JC: Notch targeting 2.0. Blood 2009, 113:6044-6045.
37. Cullion K, Draheim KM, Hermance N, Tammam J, Sharma VM, Ware C,
Nikov G, Krishnamoorthy V, Majumder PK, Kelliher MA: Targeting the
Notch1 and mTOR pathways in a mouse T-ALL model. Blood 2009,
113:6172-6181.
38. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E,
Sulis ML, Barnes K, Sawai C, Homminga I: Gamma-secretase inhibitors
reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
Nat Med 2009, 15:50-58.
39. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, Chang DZ,
Curley SA, Abdalla EK, Ellis LM, Vauthey JN: Bevacizumab improves
pathologic response and protects against hepatic injury in patients
treated with oxaliplatin-based chemotherapy for colorectal liver
metastases. Cancer 2007, 110:2761-2767.
doi:10.1186/2045-824X-3-17
Cite this article as: Yan: Therapeutic promise and challenges of
targeting DLL4/NOTCH1. Vascular Cell 2011 3:17.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Yan Vascular Cell 2011, 3:17
http://www.vascularcell.com/content/3/1/17
Page 5 of 5
